Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance. (13th October 2017)

• Record Type: Journal Article
• Authors: Duarte, Horacio A; Panpradist, Nuttada; Beck, Ingrid A; Lutz, Barry; Lai, James; Kanthula, Ruth M; Kantor, Rami; Tripathi, Anubhav; Saravanan, Shanmugam; MacLeod, Iain J; Chung, Michael H; Zhang, Guoqing; Yang, Chunfu; Frenkel, Lisa M
• Is Part Of: Journal of infectious diseases. Volume 216(2017:Nov. 15)Supplement 9
• Page Start: S824
• Page End: S828
• Publication Date: 2017-10-13
• Subjects: HIV -- drug resistance -- point-of-care tests; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jix413
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Healthcare delivery has advanced due to the implementation of point-of-care testing, which is often performed within minutes to hours in minimally equipped laboratories or at home. Technologic advances are leading to point-of-care kits that incorporate nucleic acid–based assays, including polymerase chain reaction, isothermal amplification, ligation, and hybridization reactions. As a limited number of single-nucleotide polymorphisms are associated with clinically significant human immunodeficiency virus (HIV) drug resistance, assays to detect these mutations have been developed. Early versions of these assays have been used in research. This review summarizes the principles underlying each assay and discusses strategic needs for their incorporation into the management of HIV infection.